Stock Analysis

BioRem Third Quarter 2022 Earnings: EPS: CA$0.05 (vs CA$0.003 loss in 3Q 2021)

  •  Updated
Source: Shutterstock

BioRem (CVE:BRM) Third Quarter 2022 Results

Key Financial Results

  • Revenue: CA$7.31m (up 60% from 3Q 2021).
  • Net income: CA$761.2k (up from CA$115.4k loss in 3Q 2021).
  • Profit margin: 10% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.
  • EPS: CA$0.05 (up from CA$0.003 loss in 3Q 2021).
TSXV:BRM Earnings and Revenue History November 17th 2022

All figures shown in the chart above are for the trailing 12 month (TTM) period

BioRem shares are up 7.1% from a week ago.

Risk Analysis

You still need to take note of risks, for example - BioRem has 3 warning signs (and 2 which are potentially serious) we think you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether BioRem is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis